SCHEMBL30348908

SCHEMBL30348908

CCO[C@H]1CC[C@@H](Nc2ncc3c(-c4ccc5ncccc5c4)c[nH]c3n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.51
▸ CLK2 P49760 4/20 0.51
▸ CLK3 P49761 2/20 0.51
▸ RET P07949 5/20 0.45
▸ CLK1 P49759 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ DYRK1B Q9Y463 2/20 0.43
▸ EIF2AK4 Q9P2K8 2/20 0.39
▸ CDC7 O00311 6/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ MAP4K4 O95819 3/20 0.39
▸ PIM1 P11309 3/20 0.39
▸ PRKACA P17612 3/20 0.39
▸ FLT3 P36888 3/20 0.39
▸ GSK3B P49841 3/20 0.39
▸ JAK3 P52333 3/20 0.39
▸ HIPK2 Q9H2X6 3/20 0.39
▸ DAPK3 O43293 2/20 0.39
▸ JAK2 O60674 2/20 0.39
▸ PRKD3 O94806 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25520353 1.00 DYRK1A (0.51) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25200883 0.91 DYRK1A (0.49) DYRK1ACLK2CLK3RETCLK1
SCHEMBL30349136 0.91 DYRK1A (0.49) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25265744 0.91 DYRK1A (0.49) DYRK1ACLK2CLK3RETCLK1
SCHEMBL30349409 0.91 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25523274 0.91 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25519866 0.91 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL30347165 0.90 RET (0.41) DYRK1ACLK2CLK3RETDYRK1B
SCHEMBL25520355 0.90 RET (0.41) DYRK1ACLK2CLK3RETDYRK1B
SCHEMBL25158041 0.88 DYRK1A (0.55) DYRK1ACLK2CLK3RETCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback